← All trials
NCT05490680
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2022
- Primary completion
- Aug 31, 2023
- Completion date
- Aug 31, 2023
- First posted
- Aug 8, 2022
- Last posted
- Aug 19, 2022
- Enrollment
- 600
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- IBSA Institut Biochimique SALead sponsor
- IBSA Institut Biochimique SAStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.